Pfizer Grows In Rare Disease With $810m Dwarfism Company Buy

Pfizer adds to its rare disease portfolio with purchase of Therachon, a Swiss company working in achondroplasia. But whether it can catch up with Biomarin’s Phase III vosoritide is still to be seen.